e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Pulmonary hypertension: novel insights into the biology of the disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients
Raquel Annoni (Sao Paulo, Brazil), Raquel Annoni, Ligia Couceiro, Silvio Barbosa, Tatiana Lancas, Salvatore Battaglia, Marisa Dolhnikoff, Pieter Hiemstra, Peter Sterk, Klaus Rabe, Thais Mauad
Source:
International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Session:
Pulmonary hypertension: novel insights into the biology of the disease
Session type:
Thematic Poster Session
Number:
2446
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Raquel Annoni (Sao Paulo, Brazil), Raquel Annoni, Ligia Couceiro, Silvio Barbosa, Tatiana Lancas, Salvatore Battaglia, Marisa Dolhnikoff, Pieter Hiemstra, Peter Sterk, Klaus Rabe, Thais Mauad. Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients. Eur Respir J 2015; 46: Suppl. 59, 2446
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Pulmonary vessels remodeling in COPD
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006
Expression of TGFβ-1 and TGFβ-1RII in pulmonary arteries of patients with severe COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 392s
Year: 2003
The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced COPD
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Vascular endothelial dysfunction in chronic obstructive pulmonary disease: Comparison with bronchial asthma, and controls
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary gene expression of tenascin-C and fibronectin in chronic obtructive pulmonary disease (COPD)
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Relation between pulmonary arterial remodeling and parenchymal disease in severe COPD and interstitial lung disease patients
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
microRNA profile in COPD patients with and without pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
The prevalence and characteristics of pulmonary hypertension in severe COPD
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
CT measured pulmonary artery to aorta ratio as a predictor of pulmonary hypertension in COPD
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD
Source: Eur Respir J 2002; 19: 632-638
Year: 2002
The transcription factor slug is increased in pulmonary artery endothelial cells of COPD patients
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Pulmonary vascular remodelling in COPD versus bronchial asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 82s
Year: 2003
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept